New Zealand markets closed

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
130.70+3.31 (+2.60%)
As of 12:57PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 12.04B
Enterprise value 11.76B
Trailing P/E N/A
Forward P/E 45.05
PEG ratio (5-yr expected) N/A
Price/sales (ttm)9.47
Price/book (mrq)14.01
Enterprise value/revenue 9.46
Enterprise value/EBITDA -25.92

Trading information

Stock price history

Beta (5Y monthly) 0.95
52-week change 33.76%
S&P500 52-week change 321.08%
52-week high 3159.89
52-week low 355.25
50-day moving average 3125.93
200-day moving average 3111.53

Share statistics

Avg vol (3-month) 3838.24k
Avg vol (10-day) 3844.78k
Shares outstanding 594.51M
Implied shares outstanding 693.86M
Float 889.61M
% held by insiders 14.40%
% held by institutions 186.91%
Shares short (15 Apr 2024) 44.87M
Short ratio (15 Apr 2024) 47.68
Short % of float (15 Apr 2024) 45.42%
Short % of shares outstanding (15 Apr 2024) 45.19%
Shares short (prior month 15 Mar 2024) 44.97M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:6
Last split date 312 Jul 2012

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -43.11%
Operating margin (ttm)6.21%

Management effectiveness

Return on assets (ttm)-5.24%
Return on equity (ttm)-86.15%

Income statement

Revenue (ttm)1.24B
Revenue per share (ttm)13.46
Quarterly revenue growth (yoy)53.50%
Gross profit (ttm)N/A
EBITDA -223.43M
Net income avi to common (ttm)-535.98M
Diluted EPS (ttm)-5.80
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.68B
Total cash per share (mrq)17.86
Total debt (mrq)1.4B
Total debt/equity (mrq)162.55%
Current ratio (mrq)3.95
Book value per share (mrq)9.17

Cash flow statement

Operating cash flow (ttm)-500.99M
Levered free cash flow (ttm)-347.96M